炎症疾患におけるインターロイキン-6およびインターロイキン-6受容体阻害に関するとコンセンサス: アップデート
doi: 10.1136/ard-2022-222784.
Blocking the IL-6R is a major therapeutic advance for many diseases in adults and children. Updated consensus statement provides guidance to rheumatologists and other experts, as well as patients and administrators, on managing patients with the use of drugs blocking the IL-6 pathway.